Active, Recruiting

This is a study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.

This is a study to assess adverse events and change in disease activity in adult participants receiving intravenously infused Telisotuzumab Adizutecan alone or with standard of care in participants with post adjuvant circulating tumor DNA positive colorectal cancer and no radiographic evidence of disease.

This is an observational study, monitoring participants while receiving standard-of-care biomarker-directed therapy with the goal to learn about the effects of these therapies on ctDNA in participants with minimal residual colorectal cancer.

This is a Phase 2 trial studying anti-CSF1R antibody in patients with ctDNA positive colorectal cancer minimal residual disease after completion of standard therapies.

This is a Phase Ib, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

This is a study designed to evaluate varying doses of TROP2-CAR-NK cells combined with cetuximab and their ability to clear ctDNA in patients with minimal residual colorectal cancer.

This is a Phase III trial studying atezolizumab and bevacizumab in ctDNA positive colorectal cancer patients with no evidence of cancer on imaging after completing standard therapies.

This is a single arm Phase II cohort of RO7198457 in patients with circulating tumor DNA (ctDNA) positive surgically resected Stage IV CRC after standard of care adjuvant therapy. The study will test whether the vaccine can reduce recurrence of the cancer.

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal or colon. The study will test whether the vaccine can reduce recurrence of the cancer.